Document is current

Any future updates will be listed below

Treatment outcomes in elderly patients ≥ 65 years with Large B-Cell Lymphoma (LBCL): a real-world single center experience focusing on potential CD19-CAR-T eligibility in second line

Crossref DOI link: https://doi.org/10.1007/s00277-025-06478-9

Published Online: 2025-06-27

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark